Loading
journalsJournal
Journal of hematology & oncology
A large open access journal spanning blood cancers and solid tumours, from laboratory mechanisms to clinical trials. Read by haematologists, oncologists and translational researchers.
Also called: J Hematol OncolJHO
Overview
The journal is published by BMC, part of Springer Nature, and describes itself as an open access journal publishing top-quality research encompassing all aspects of haematology and oncology, serving as an international platform for sharing laboratory and clinical findings among laboratory scientists, physician scientists, haematologists and oncologists. It publishes research articles, reviews and research highlights on topical subjects from leading experts. NLM catalogues it from 2008 as a free open access electronic journal published by BioMed Central, noting that as an online journal it has no issue numbers and each volume corresponds to a calendar year. The Directory of Open Access Journals lists it as open access since 2008 with anonymous peer review, an article processing charge, and CC BY and CC BY-NC-ND licences.
Publisher
BMC (Springer Nature)
Scope
haematological oncology and oncology
Website
Access model
open access
Founded
2008
ISSN
1756-8722
rct202513 citations
PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy
This is the paper Europe PMC returns for registry id NCT03706690 with the most citations, so it is the natural first reading for anyone following the PACIFIC-5 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
observational202519 citations
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies
This is the paper Europe PMC returns for registry id NCT04152499 with the most citations, so it is the natural first reading for anyone following the TROP2 ADC trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
observational2018427 citations
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
One trial page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Ernst J. Kuipers
Representative of Netherlands Comprehensive Cancer Organisation (IKNL) to the Organisation of European Cancer Institutes
Cancer centre representation (OECI)
Ernst J. Kuipers represents Netherlands Comprehensive Cancer Organisation (IKNL) in the Organisation of European Cancer Institutes, which lists the centre among its members in The Netherlands.
Lim Soon Thye
Chief Executive Officer
LymphomaMedical oncologyHealth system leadership
Lymphoma specialist and Chief Executive Officer of the National Cancer Centre Singapore, the country's largest public cancer centre.
Yu Jinming
President (院长), Shandong Cancer Hospital and Institute
Radiation oncologyHospital managementCancer research
Academician of the Chinese Academy of Engineering who is President of Shandong Cancer Hospital and Institute, the provincial cancer hospital in Jinan.
Yuquan Wei
Professor; Director, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University
Cancer biotherapyGene therapyVaccines
Built China's flagship biotherapy laboratory, a source of cancer vaccines, gene therapies, and biologics.
rctJournal of hematology & oncology 202513 citations
PACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapy
This is the paper Europe PMC returns for registry id NCT03706690 with the most citations, so it is the natural first reading for anyone following the PACIFIC-5 trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
observationalJournal of hematology & oncology 202519 citations
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies
This is the paper Europe PMC returns for registry id NCT04152499 with the most citations, so it is the natural first reading for anyone following the TROP2 ADC trial. Read the abstract above alongside the trial page and the registry entry; the record was linked automatically and its figures have not been checked by hand.
observationalJournal of hematology & oncology 2018427 citations
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
One trial page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Similar pages
- JournalMolecular cancer
Shares Yuquan Wei, PubMed & Europe PMC.
- JournalAmerican Society of Clinical Oncology educational book
Shares Lim Soon Thye, PubMed & Europe PMC.
- JournalBlood cancer discovery
Shares PubMed & Europe PMC, Chronic lymphocytic leukaemia, Acute myeloid leukaemia, Multiple myeloma.
- TrialLEGEND-2
Shares A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma, Multiple myeloma.
- JournalCancer treatment reviews
Shares Yu Jinming, PubMed & Europe PMC.
- JournalCurrent hematologic malignancy reports
Shares PubMed & Europe PMC, Chronic lymphocytic leukaemia, Acute myeloid leukaemia, Multiple myeloma.
- JournalClinical lymphoma, myeloma & leukemia
Shares PubMed & Europe PMC, Chronic lymphocytic leukaemia, Acute myeloid leukaemia, Multiple myeloma.
- JournalLeukemia & lymphoma
Shares PubMed & Europe PMC, Chronic lymphocytic leukaemia, Acute myeloid leukaemia, Multiple myeloma.
cancers
collections
people
key papers
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myelomaPACIFIC-5: a phase III clinical trial of consolidation durvalumab in patients with unresectable stage III NSCLC and no progression after concurrent or sequential chemoradiotherapyResults of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies